Swiss National Bank Ngm Biopharmaceuticals Inc Transaction History

Swiss National Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$2.44 - $4.53 $89,060 - $165,345	36,500 Added 59.16%	98,200 $254,000
Q1 2023 May 10, 2023	SELL	$3.72 - $5.4 $15,252 - $22,140	-4,100 Reduced 6.23%	61,700 $251,000
Q3 2022 Nov 09, 2022	BUY	$12.59 - $17.67 $22,662 - $31,806	1,800 Added 2.81%	65,800 $861,000
Q2 2022 Aug 09, 2022	SELL	$10.58 - $17.5 $100,510 - $166,250	-9,500 Reduced 12.93%	64,000 $820,000
Q1 2022 May 09, 2022	BUY	$13.81 - $18.6 $81,479 - $109,740	5,900 Added 8.73%	73,500 $1.12 Million
Q2 2021 Aug 06, 2021	BUY	$15.06 - $30.03 $1.02 Million - $2.03 Million	67,600 New	67,600 $1.33 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.